Business
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences. \n\n \n \n \n \n \n \n\n \nDetails of the company's participation are as follows:\nCiti's 16th Annual Biopharma Virtual Conference Details: Viking management will participate in 1-on-1 meetings Conference Dates: September 8-10, 2021 Format: Virtual conferenceH.C. Wainwright 23rd Annual Global Investment Conference Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference Dates: September 13-15, 2021 Presentation Timing: Available online at 7:00 a.m. Eastern on Monday, September 13, 2021 Format: Virtual conference Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference Dates: September 20-23, 2021 Presentation Timing: Tuesday, September 21, 2021 at 2:55 p.m. Eastern Format: Virtual conference, webcast availableCantor Fitzgerald Virtual Global Healthcare Conference Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference Dates: September 27-30, 2021 Presentation Timing: Thursday, September 30, 2021 at 2:00 p.m. Eastern Format: Virtual conferenceA webcast of the Oppenheimer presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences. \nAbout Viking Therapeutics, Inc. \nViking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently bei...